Register
Pirfenidone increases survival in patients with idiopathic pulmonary fibrosis |
Journal Updates
eMediNexus Coverage from: 
Pirfenidone increases survival in patients with idiopathic pulmonary fibrosis
eMediNexus,  22 January 2019
remove_red_eye 628 Views
#Internal Medicine #Pharmacist #Pulmonary Medicine

0 Read Comments                

Pirfenidone treatment increased 3-year survival rates in patients who have idiopathic pulmonary fibrosis (IPF) and resulted in a 30% survival benefit compared with patients who have not been treated with antifibrotic agents, according to a retrospective observational intention-to-treat study reported online Nov. 23, 2018 in BMC Pulmonary Medicine.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!